BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//https://takethedate.it///NONSGML kigkonsult.se iCalcreator 2.10.15//
METHOD:PUBLISH
BEGIN:VEVENT
UID:20260615T203705CEST-6995ValvMG@https://takethedate.it/
DTSTAMP:20260615T183705Z
DESCRIPTION:Napoli (NA)\, Hotel Royal Continental - Via Partenope\, 38/44 d
 al 5 dicembre 2019 al 7 dicembre 2019\n\nRecent insights into the genetic 
 and somatic aberrations have initiated a new era of rapidly evolving treat
 ments for melanoma.\nThe possibility to use targeted and immune-based drug
 s alone\, in combination\, or in sequence\, able to improve responses to o
 vercome the resistance\, to potentiate the action of immune system with th
 e new immunomodulating antibodies\, and identification of biomarkers that 
 can predict the response to a particular therapy\, represent actual concep
 ts and approaches in the clinical management of melanoma.\nMelanoma treatm
 ent landscape changed in 2011 with the approval of the first anti-cytotoxi
 c T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the
  first BRAF-targeted monoclonal antibody\, both of which significantly imp
 roved overall survival.\nSince then\, improved understanding of the tumor 
 microenvironment and tumor immuno-evasion strategies has resulted in diffe
 rent approaches to target and harness the immune response.\nApproval of ne
 w immune- and target-therapies have further improved outcomes for patients
  with advanced melanoma.\nThe therapies offer the opportunity for various 
 approaches with distinct modes of action being used in combination with on
 e another\, as well as combined with other treatment modalities such as ra
 diotherapy\, electrochemotherapy and surgery.\nLatest findings in melanoma
  research and advances on themes of paramount importance for melanoma prev
 ention\, diagnosis and treatment\, will be discussed in the session dedica
 ted to system biology on immunotherapy\, immunogenicity and gene expressio
 n profiling\, in the two sessions focused on the progresses of melanoma re
 search on biomarkers/precision medicine and on combination strategies\, re
 spectively.\nConclusions will be drawn after the “Great Debate” session\, 
 where counterpoint views from leading experts on specific controversial cl
 inical issues will be presented and discussed from different points of vie
 w:\n\nlocal or systemic treatment?\nDo we really need to treat stage IIIA 
 patients with adjuvant?\nWhat time is better to change treatment: progress
 ion disease or stable disease?\nAdoptive cell therapy before or in combina
 tion with check point inhibitors?\nCan we stop the treatment on while resp
 onse?\n\nIn order to disclose and stimulate the discussion of new approach
 es and strategies in the field of melanoma  and\, based on the increasing 
 success of “Melanoma Bridge” events over the years since 2011\, a panel of
  international faculty will join the congress that will be held in Decembe
 r 2019.\nPresidents of the event are Paolo A. Ascierto (National Cancer In
 stitute\, “Fondazione G. Pascale”\, Naples\, Italy)\, Igor Puzanov (Roswel
 l Park Comprehensive Cancer Center\, Buffalo\, New York\, USA) and Corrado
  Caracò Ascierto (National Cancer Institute\, “Fondazione G. Pascale”\, Na
 ples\, Italy)\, who will gather with the international faculty members in 
 an interactive atmosphere which stimulates discussion and exchange of thei
 r experience regarding the most recent advances in research and clinical m
 anagement of melanoma patients.\nQuesto evento sarà accreditato per le seg
 uenti professioni:\nBIOLOGO\nFARMACISTA \nINFERMIERE\nINFERMIERE PEDIATRIC
 O\nMEDICO CHIRURGO \n https://takethedate.it/Eventi/15048-melanoma-bridge-
 2019.html
DTSTART:20191205T070000Z
DTEND:20191207T160000Z
LOCATION:Hotel Royal Continental Napoli (Via Partenope 38/44\, Napoli)
SUMMARY:Melanoma Bridge 2019
URL:https://takethedate.it/Eventi/15048-melanoma-bridge-2019.html
END:VEVENT
END:VCALENDAR